TABLE 2.
The baseline and clinicopathological characteristics of patients with metastatic CMA.
| Parameter | Number | Percentage (%) |
|---|---|---|
| Gender (male) | 22 | 52.38 |
| Age (>60 year) | 8 | 19.05 |
| Smoking (yes) | 5 | 11.90 |
| Drinking(yes) | 3 | 7.14 |
| Diabetes (yes) | 4 | 9.52 |
| Hypertension (yes) | 2 | 4.76 |
| T stage (T3‐4) | 31 | 73.81 |
| LN status (N1‐2) | 18 | 42.86 |
| Differentiation (G1‐2) | 16 | 38.10 |
| Cancer bulk (>5 cm) | 13 | 30.95 |
| Primary location (right) | 22 | 52.38 |
| Palliative surgery (yes) | 22 | 52.38 |
| Chemotherapy(yes) | 41 | 97.62 |
| Radiotherapy (yes) | 6 | 14.29 |
| Targeted therapy (yes) | 8 | 19.05 |
| CEA (>5 ng/mL) | 22 | 52.38 |
| CA19‐9 (>37 U/mL) | 24 | 57.14 |
| NAR (score=1) | 10 | 23.81 |
| NPAR (score=1) | 14 | 33.33 |
| AFR (score=1) | 32 | 76.19 |
| FPR (score=1) | 16 | 38.10 |
| Progression rate | 38 | 90.48 |
LN: lymph node; NAR: neutrophil‐to‐albumin×100; NPAR: neutrophil‐to ‐pre‐albumin ratio×1000; AFR: albumin‐to‐fibrinogen ratio; FPR: fibrinogen‐to‐ pre‐albumin ratio ×1000; right location means the caecum, ascending colon, and transverse colon, the others were considered as left tumor location.